Lucy Gilbert, MD, on Mirvetuximab Soravtansine Plus Bevacizumab for Platinum-Agnostic Ovarian Cancer

Posted: Monday, June 15, 2020

Lucy Gilbert, MD, of McGill University Health Center, discusses data showing mirvetuximab soravtansine plus bevacizumab is active with a favorable tolerability profile in patients with recurrent ovarian cancer regardless of platinum sensitivity.